Semaglutide Patent Cliff 2026: Generic GLP-1 Peptides to Reshape Supply Chains
Semaglutide patents expire in 2026 in India, China and Brazil, opening the GLP-1 market to generics. Here is what it means for peptide supply, clinics and research buyers.